$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

$halo Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-Q Financial Statement

#000115903614000042 Filed on May 12, 2014

Income Statement

Concept	2014 Q1	2013 Q1
Revenue	$11.97M	$11.83M
YoY Change	1.12%	59.04%
Cost Of Revenue	$5.520M	$739.0K
YoY Change	646.96%	944.36%
Gross Profit	$3.048M	$769.0K
YoY Change	296.36%	559.24%
Gross Profit Margin	25.47%	6.5%
Selling, General & Admin	$10.25M	$7.556M
YoY Change	35.65%	14.16%
% of Gross Profit	336.29%	982.57%
Research & Development	$21.42M	$22.03M
YoY Change	-2.81%	38.66%
% of Gross Profit	702.59%	2865.28%
Depreciation & Amortization	$397.0K	$295.0K
YoY Change	34.58%	24.06%
% of Gross Profit	13.02%	38.36%
Operating Expenses	$31.67M	$29.59M
YoY Change	7.01%	31.45%
Operating Profit	-$25.22M	-$18.50M
YoY Change	36.36%	22.16%
Interest Expense	$1.376M	$848.0K
YoY Change	62.26%
% of Operating Profit
Other Income/Expense, Net	$47.00K	$55.00K
YoY Change	-14.55%	159.23%
Pretax Income	-$26.50M	-$19.30M
YoY Change	37.31%	27.81%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$26.55M	-$19.29M
YoY Change	37.63%	27.58%
Net Earnings / Revenue	-221.86%	-163.01%
Basic Earnings Per Share
Diluted Earnings Per Share	-$222.9K	-$171.7K
COMMON SHARES
Basic Shares Outstanding	124.0M shares	113.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$164.5M	$87.43M
YoY Change	88.16%	-25.02%
Cash & Equivalents	$76.57M	$39.02M
Short-Term Investments	$87.90M	$48.41M
Other Short-Term Assets	$8.700M	$10.60M
YoY Change	-17.92%	19.1%
Inventory	$6.765M	$2.737M
Prepaid Expenses
Receivables	$10.96M	$10.38M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$190.9M	$111.1M
YoY Change	71.82%	-16.21%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.628M	$3.975M
YoY Change	-8.73%	80.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.100M	$1.800M
YoY Change	72.22%
Total Long-Term Assets	$6.773M	$5.756M
YoY Change	17.67%	174.09%
TOTAL ASSETS
Total Short-Term Assets	$190.9M	$111.1M
Total Long-Term Assets	$6.773M	$5.756M
Total Assets	$197.7M	$116.9M
YoY Change	69.16%	-13.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.658M	$2.885M
YoY Change	200.13%	-3.84%
Accrued Expenses	$12.27M	$9.178M
YoY Change	33.72%	27.47%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.404M	$1.362M
YoY Change	76.5%
Total Short-Term Liabilities	$36.36M	$19.75M
YoY Change	84.1%	18.27%
LONG-TERM LIABILITIES
Long-Term Debt	$47.40M	$29.80M
YoY Change	59.06%
Other Long-Term Liabilities	$2.343M	$436.8K
YoY Change	436.34%	-98.82%
Total Long-Term Liabilities	$2.343M	$436.8K
YoY Change	436.34%	-98.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$36.36M	$19.75M
Total Long-Term Liabilities	$2.343M	$436.8K
Total Liabilities	$38.70M	$20.19M
YoY Change	91.72%	-62.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$408.6M	-$317.9M
YoY Change	28.55%
Common Stock	$475.4M	$349.6M
YoY Change	35.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$66.75M	$31.68M
YoY Change
Total Liabilities & Shareholders Equity	$197.7M	$116.9M
YoY Change	69.16%	-13.24%

Cashflow Statement

Concept	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$26.55M	-$19.29M
YoY Change	37.63%	27.58%
Depreciation, Depletion And Amortization	$397.0K	$295.0K
YoY Change	34.58%	24.06%
Cash From Operating Activities	-$17.63M	-$10.75M
YoY Change	64.0%	-44.47%
INVESTING ACTIVITIES
Capital Expenditures	$411.0K	$534.0K
YoY Change	-23.03%
Acquisitions
YoY Change
Other Investing Activities	-$42.80M	-$48.90M
YoY Change	-12.47%
Cash From Investing Activities	-$43.19M	-$49.48M
YoY Change	-12.71%	-312401.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$107.7M	$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$110.0M	-$252.0K
YoY Change	-43764.29%	-100.3%
NET CHANGE
Cash From Operating Activities	-$17.63M	-$10.75M
Cash From Investing Activities	-$43.19M	-$49.48M
Cash From Financing Activities	$110.0M	-$252.0K
Net Change In Cash	$49.21M	-$60.48M
YoY Change	-181.37%	-194.83%
FREE CASH FLOW
Cash From Operating Activities	-$17.63M	-$10.75M
Capital Expenditures	$411.0K	$534.0K
Free Cash Flow	-$18.04M	-$11.28M
YoY Change	59.88%	-41.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3135000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8658000	USD
CY2014Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	11682000	USD
CY2013Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	9707000	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10956000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9097000	USD
CY2013Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-182000	USD
CY2014Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1035000	USD
CY2014Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	13022000	USD
CY2013Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14920000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14369000	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12272000	USD
CY2014Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7961000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7649000	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	17000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	361930000	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	475249000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2397000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3295000	USD
CY2014Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	746000	USD
CY2013Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	470000	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9600000	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9100000	shares
CY2013Q4	us-gaap	Assets Assets	101793000	USD
CY2014Q1	us-gaap	Assets Assets	197687000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	95195000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	190914000	USD
CY2013Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	49856000	USD
CY2014Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	160606000	USD
CY2014Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	87919000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	44146000	USD
CY2014Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	87944000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	44129000	USD
CY2014Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	87919000	USD
CY2013Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	44146000	USD
CY2014Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	35300000	USD
CY2014Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	52600000	USD
CY2014Q1	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	17000	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	20000	USD
CY2014Q1	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	42000	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	3000	USD
CY2014Q1	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	10
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27357000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76570000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39018000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99501000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-60483000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	49213000	USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	114533000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124483000	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124483000	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	114533000	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	115000	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	124000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19317000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26590000	USD
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5520000	USD
CY2013Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	739000	USD
CY2014Q1	us-gaap	Costs And Expenses CostsAndExpenses	37185000	USD
CY2013Q1	us-gaap	Costs And Expenses CostsAndExpenses	30329000	USD
CY2014Q1	us-gaap	Debt Instrument Covenant Compliance DebtInstrumentCovenantCompliance	2014-03-31
CY2013Q4	us-gaap	Deferred Revenue DeferredRevenue	53143000	USD
CY2014Q1	us-gaap	Deferred Revenue DeferredRevenue	57873000	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13026000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7398000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	45745000	USD
CY2014Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	44847000	USD
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	USD
CY2013Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	300000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	295000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	397000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7075000	USD
CY2014Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3203000	USD
CY2014Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2013Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1981000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3419000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5327000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1859000	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3201000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4729000	USD
CY2013Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	67000	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	595000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	43000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	73000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1211000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	252000	USD
CY2013Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	100000	USD
CY2014Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	848000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	1376000	USD
CY2013Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	800000	USD
CY2014Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1400000	USD
CY2014Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	964000	USD
CY2013Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	753000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	6170000	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	6765000	USD
CY2014Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1018000	USD
CY2013Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1137000	USD
CY2014Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	4783000	USD
CY2013Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	4280000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	101793000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	197687000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	36360000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24902000	USD
CY2013Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	10325000	USD
CY2014Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	2599000	USD
CY2013Q4	us-gaap	Long Term Debt LongTermDebt	49772000	USD
CY2014Q1	us-gaap	Long Term Debt LongTermDebt	47389000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2014Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	2404000	USD
CY2014Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is a science-driven, biopharmaceutical company committed to making molecules into medicines for patients in need. Our research focuses primarily on human enzymes that alter the extracellular matrix. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary enzymes can be used to facilitate the delivery of injected drugs and fluids, thus enhancing the efficacy and the convenience of other drugs or to alter abnormal tissue structures for clinical benefit. We have chosen to exploit our technology and expertise in a balanced way to modulate both risk and spend by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, such as diabetes, oncology and dermatology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products which combine our technology with the collaborators' proprietary compounds. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of the product candidates in our current pipeline are based on rHuPH20, a patented human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid - a naturally occurring substance that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We have one proprietary commercial product, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> recombinant. Our proprietary pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. We currently have collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Pfizer Inc. (“Pfizer”) and Baxter Healthcare Corporation (“Baxter”), with three approved products for marketing in Europe, one product candidate which has been submitted for regulatory approval in the U.S. and several others at various stages of development.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were founded in 1998 and reincorporated from the State of Nevada to the State of Delaware in November 2007. Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these Notes to Condensed Consolidated Financial Statements refer to Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.'s wholly owned subsidiary, Halozyme Holdings Ltd.</font></div></div>
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-252000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	110034000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43191000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49481000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17630000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10750000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-26548000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-19288000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-25219000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18495000	USD
CY2014Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1647000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1235000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	18000	USD
CY2014Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	700000	USD
CY2014Q1	us-gaap	Other Assets OtherAssets	662000	USD
CY2013Q4	us-gaap	Other Assets OtherAssets	356000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-42000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-29000	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2343000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1364000	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	55000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	47000	USD
CY2013Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1339000	USD
CY2014Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	921000	USD
CY2013Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	309000	USD
CY2014Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	853000	USD
CY2013Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	48947000	USD
CY2014Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	65005000	USD
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	411000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	534000	USD
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	11101000	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	11349000	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8704000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8425000	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2645000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2676000	USD
CY2014Q1	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	600000	USD
CY2014Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain prior period amounts have been reclassified to conform to current period presentation. Specifically, we have reclassified </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> from accrued expenses to other long-term liabilities in the consolidated balance sheet at December 31, 2013.</font></div></div>
CY2014Q1	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107713000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	57000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3174000	USD
CY2014Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	22225000	USD
CY2013Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2014Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11589000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11071000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3422000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3628000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21415000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22034000	USD
CY2014Q1	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	4617000	USD
CY2013Q4	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	1505000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-382052000	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-408600000	USD
CY2014Q1	us-gaap	Revenues Revenues	11966000	USD
CY2013Q1	us-gaap	Revenues Revenues	11834000	USD
CY2014Q1	us-gaap	Royalty Revenue RoyaltyRevenue	799000	USD
CY2013Q1	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2014Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	13.00
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	8568000	USD
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1509000	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10250000	USD
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7556000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2397000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3295000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7400000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8700000	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8846153	shares
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	66748000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-19990000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	118943000	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112417000	shares
CY2013Q4	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	3707000	USD
CY2014Q1	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	5511000	USD
CY2014Q1	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	1554000	USD
CY2013Q4	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	4495000	USD
CY2014Q1	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	5629000	USD
CY2013Q4	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	3377000	USD
CY2014Q1	halo	Accrued Outsourced Researchand Development Expenses Long Term AccruedOutsourcedResearchandDevelopmentExpensesLongTerm	750000	USD
CY2013Q4	halo	Accrued Outsourced Researchand Development Expenses Long Term AccruedOutsourcedResearchandDevelopmentExpensesLongTerm	551000	USD
CY2013Q4	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	3233000	USD
CY2014Q1	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	2543000	USD
CY2014Q1	halo	Additional Maximum Proceeds Receivablefrom Collaboratorof Licenseand Collaborative Agreement Upon Achievementof Clinical Development Milestones AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones	55000000	USD
CY2014Q1	halo	Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets	12000000	USD
CY2013Q4	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	610000	USD
CY2014Q1	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	726000	USD
CY2013Q4	halo	Prepaidmanufacturingexpense Prepaidmanufacturingexpense	5884000	USD
CY2014Q1	halo	Prepaidmanufacturingexpense Prepaidmanufacturingexpense	6116000	USD
CY2013Q4	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	3522000	USD
CY2014Q1	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	3650000	USD
CY2014Q1	halo	Stock Issued During Period Shares New Issues To Underwriter StockIssuedDuringPeriodSharesNewIssuesToUnderwriter	1153846	shares
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001159036
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	124508798	shares
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	HALOZYME THERAPEUTICS INC

Files In Submission

Name	View Source	Status
0001159036-14-000042-index-headers.html	Edgar Link	pending
0001159036-14-000042-index.html	Edgar Link	pending
0001159036-14-000042.txt	Edgar Link	pending
0001159036-14-000042-xbrl.zip	Edgar Link	pending
ex10_2separationagreement.htm	Edgar Link	pending
ex311q12014.htm	Edgar Link	pending
ex312q12014.htm	Edgar Link	pending
ex32q12014.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
halo-20140331.xml	Edgar Link	completed
halo-20140331.xsd	Edgar Link	pending
halo-20140331_cal.xml	Edgar Link	unprocessable
halo-20140331_def.xml	Edgar Link	unprocessable
halo-20140331_lab.xml	Edgar Link	unprocessable
halo-20140331_pre.xml	Edgar Link	unprocessable
halo1q2014-10q.htm	Edgar Link	pending
pipelineslideapril2014.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

2014 Q1 Form 10-Q Financial Statement

#000115903614000042 Filed on May 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO HALOZYME THERAPEUTICS, INC. Stock $halo

2014 Q1 Form 10-Q Financial Statement

#000115903614000042 Filed on May 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo